Adverse drug reactions (ADRs) are associated with clinical morbidity and, in severe cases, even mortality.
Globally billions of dollars are spent on managing these ADRs for common and uncommon diseases. The developing
world suffers from a high burden of tuberculosis, which requires 6-8 months of multi-drug treatment. In
spite of most cases being treatable the problem persists mainly due to a high attrition rate associated with ADR
mediated complications. Due to these reasons drug resistant strains have emerged and are now a serious challenge
to TB eradication. To effectively deliver the available treatment regimen and ensure patient compliance it is important
to manage ADRs more efficiently. Recent studies have demonstrated that drug outcomes are patient-specific
and can, therefore be predicted. A few of these drugs, including a few administered for TB, have shown excellent correlation with response
rates and development of ADRs. In this review, we profile information available in public domain for existing anti-TB drugs to
understand the genesis of ADRs and patient response. Additionally, human genome variation databases have been used to correlate the
frequency of these markers and their genomic variants in different populations.
Keywords: Adverse drug reactions, allele, anti-tuberculosis drugs, genetic marker, pharmacogenomics, side effects, single nucleotide
Rights & PermissionsPrintExport